Inspire Medical Systems Revenue and Competitors

Location

$319.4M

Total Funding

Estimated Revenue & Valuation

  • Inspire Medical Systems's estimated annual revenue is currently $201M per year.(i)
  • Inspire Medical Systems received $75.0M in venture funding in December 2018.
  • Inspire Medical Systems's estimated revenue per employee is $212,025
  • Inspire Medical Systems's total funding is $319.4M.
  • Inspire Medical Systems's current valuation is $6.5B. (January 2022)

Employee Data

  • Inspire Medical Systems has 948 Employees.(i)
  • Inspire Medical Systems grew their employee count by 86% last year.

Inspire Medical Systems's People

NameTitleEmail/Phone
1
Area VPReveal Email/Phone
2
Area VP SalesReveal Email/Phone
3
Zone VP SalesReveal Email/Phone
4
Area VPReveal Email/Phone
5
Area VP FloridaReveal Email/Phone
6
Zone VPReveal Email/Phone
7
CFOReveal Email/Phone
8
Area VPReveal Email/Phone
9
VP Program Management OrganizationReveal Email/Phone
10
SVP SalesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$30.6M1224%N/AN/A
#2
$18.6M7435%N/AN/A
#3
$75.6M30120%N/AN/A
#4
$12M484%N/AN/A
#5
$2.8M1110%N/AN/A
#6
$3M120%N/AN/A
#7
$24.6M985%N/AN/A
#8
$11.5M4621%N/AN/A
#9
$7.3M294%N/AN/A
#10
$13.8M55-10%N/AN/A
Add Company

What Is Inspire Medical Systems?

Inspire Medical Systems, Inc. has developed the world's first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient's unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Inspire therapy works inside your body, and with your natural breathing process. It might be right for you if you have been diagnosed with OSA, and can't use or don't get relief from CPAP/BiPAP. To learn more, please visit us at www.inspiresleep.com.

keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals

$319.4M

Total Funding

948

Number of Employees

$201M

Revenue (est)

86%

Employee Growth %

$6.5B

Valuation

N/A

Accelerator

Inspire Medical Systems News

2022-04-20 - Inspire Medical Systems invests in EnsoData and Ognomy

Sleep apnea treatment developer Inspire Medical Systems has invested in two private companies with digital health tech that could better...

2022-04-19 - Inspire Medical Systems, Inc. Announces Investments in ...

Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for...

2022-04-17 - Inspire Medical Systems (INSP) to Release Quarterly Earnings ...

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for...

2021-03-03 - INSPIRE MEDICAL SYSTEMS, INC. Inspire Medical : 2020 Annual Report PDF Format Download PDF 2.04 MB

On the cover: No mask. No hose. Just sleep. Inspire patients remember their "Inspire Day," the day they received Inspire therapy, as a life changing day. For many it feels almost like a second birthday. An Inspire Day is a turning point-a day when those who have struggled with untreated obstru ...

2021-03-03 - Inspire Medical : 2020 Annual Report PDF Format Download PDF 2.04 MB

On the cover: No mask. No hose. Just sleep. Inspire patients remember their "Inspire Day," the day they received Inspire therapy, as a life changing day. For many it feels almost like a second birthday. An Inspire Day is a turning point-a day when those who have struggled with untreated obstru ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$307.1M15674%N/A
#2
$794.2M160779%N/A
#3
$694.5M2756N/AN/A

Inspire Medical Systems Funding

DateAmountRoundLead InvestorsReference
2014-05-16$40.0MEOrbiMedArticle
2016-11-10$12.5MUndisclosedArticle
2016-11-21$37.5MFAmzak HealthArticle
2018-12-19$75.0MUndisclosedArticle